Welcome to our dedicated page for Senestech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking EPA milestones, cash burn, or insider confidence around SenesTech’s game-changing fertility control for rats often means sifting through dense biotechnology disclosures. Our platform solves that problem immediately. Stock Titan’s AI reads every SenesTech SEC filing the moment it hits EDGAR and translates regulatory jargon into plain language summaries, so you see the impact on ContraPest and Evolve without spending hours decoding footnotes.
Need the SenesTech quarterly earnings report 10-Q filing to gauge sales traction? Curious about a sudden share spike and want SenesTech insider trading Form 4 transactions in real time? Each document—10-K, 10-Q, 8-K, DEF 14A—appears seconds after release, paired with AI-powered highlights that surface R&D expense trends, distributor contract details, and environmental compliance data. Investors often ask, “How do I read the SenesTech annual report 10-K simplified?” or “Where are SenesTech executive stock transactions Form 4 listed?” The answers are one click away, with pop-up explanations and side-by-side metric tracking.
Whether you’re monitoring SenesTech proxy statement executive compensation, comparing revenue guidance across quarters, or reviewing an unexpected SenesTech 8-K material events explained, our coverage stays comprehensive. AI extracts key numbers, flags material risks, and even links related SenesTech earnings report filing analysis. Use the dashboard to set alerts for SenesTech Form 4 insider transactions real-time or get bite-size notes for understanding SenesTech SEC documents with AI. Complex biotech filings, made clear, so you spend less time reading and more time making informed decisions.
SenesTech, Inc. filed an S-3 shelf prospectus registering shares underlying warrants and common stock for resale by selling stockholders; its common stock trades on Nasdaq under the symbol SNES. The prospectus states proceeds will not be received by the company except for cash from any warrant exercises, which the company intends to use for general corporate purposes including R&D, capital expenditures, working capital and potential acquisitions though no commitments exist.
The filing highlights the company’s rodent fertility-control products (ContraPest and Evolve), asserts beliefs about product palatability and population impacts, and warns of continued operating losses, dependence on successful commercialization and regulatory approvals, and dilution risk from outstanding warrants and potential exercises subject to beneficial ownership limits. The prospectus discloses multiple selling stockholders and related warrant mechanics and includes exhibits, legal and accounting consents, indemnification provisions and customary plan-of-distribution methods.
SenesTech, Inc. (a Delaware corporation with principal place in Surprise, Arizona) filed a Form D disclosing a Regulation D private offering of common stock warrants that raised an aggregate of $273,539. The filing reports the total amount sold as $273,539 with $0 remaining to be sold and indicates the offering relied on Rule 506(b). Five investors participated and the issuer states $0 of the gross proceeds were used to pay named executive officers.
The placement agent disclosed is H.C. Wainwright & Co., LLC, and the filing estimates sales commissions of $474,589. It also discloses placement agent warrants to purchase up to 72,944 shares at an exercise price of $5.4219 per share, plus accountable expenses and a management fee. The offering is not tied to a business combination and is not intended to last more than one year.
PFS Cap Mgt Co and PFS Trust report beneficial ownership of 340,000 shares of SenesTech, Inc., representing 9.99% of the outstanding common stock based on 2,247,691 shares outstanding as of June 24, 2025, per the company's Prospectus Supplement No. 2. The reported position includes 120,000 shares issuable upon exercise of warrants held by the Trust but those warrants are subject to a 9.99% exercise blocker, so the Reporting Persons cannot currently exercise all warrants to exceed the 9.99% threshold. The filing shows shared voting and dispositive power over 340,000 shares and no sole voting or dispositive power. The Schedule 13G/A is signed by John David Kessler on August 12, 2025.
FAQ
What is the current stock price of Senestech (SNES)?
What is the market cap of Senestech (SNES)?
